Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor VIII - Takeda

Next Previous
X
Search
Drug Profile

Factor VIII - Takeda

Alternative Names: Factor VIII autologous cell therapy - Takeda; Factor VIII autologous cell therapy - Transkaryotic Therapies; Factor VIII cell therapy - Takeda; Factor VIII cell therapy - Transkaryotic Therapies; Factor VIII replacement therapy - Takeda; FVIII therapy - Takeda

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Rani Therapeutics; Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for research development in Haemophilia-A in Ireland (PO, Capsule)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 06 Dec 2017 Early research in Haemophilia A in Ireland (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top